Chitosan oligosaccharides alleviate cognitive deficits in an amyloid-β1-42-induced rat model of Alzheimer's disease

International Journal of Biological Macromolecules

Volumn 83, Issue , 2016, Pages 416-425

  Jia, Shiliang ^a   Lu, Zheng ^a   Gao, Zhaolan ^a   An, Jun ^a   Wu, Xueling ^a   Li, Xiaoxiao ^a   Dai, Xueling ^a   Zheng, Qiusheng ^b   Sun, Yaxuan ^a  

^a BEIJING UNION UNIVERSITY   (China)

^b BINZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Alzheimer's disease; Amyloid 1 42; Chitosan oligosaccharides; Neuroinflammation; Oxidative stress

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; AMYLOID BETA PROTEIN[1-42]; CHITOSAN OLIGOSACCHARIDE; GLUTATHIONE PEROXIDASE; INTERLEUKIN 1BETA; MALONALDEHYDE; NEUROPROTECTIVE AGENT; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); CHITOSAN; OLIGOSACCHARIDE; PEPTIDE FRAGMENT;

ADULT; ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFECT; ENZYME ACTIVITY; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; LEARNING DISORDER; MALE; MEMORY DISORDER; MORRIS WATER MAZE TEST; NEUROMODULATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PASSIVE AVOIDANCE TEST; RAT; TUNEL ASSAY; ANIMAL; AVOIDANCE BEHAVIOR; CHEMISTRY; COGNITION; DISEASE MODEL; DRUG EFFECTS; MAZE TEST; METABOLISM; NERVE CELL; PATHOLOGY; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; APOPTOSIS; AVOIDANCE LEARNING; CHITOSAN; COGNITION; DISEASE MODELS, ANIMAL; GLUTATHIONE PEROXIDASE; HIPPOCAMPUS; MALE; MALONDIALDEHYDE; MAZE LEARNING; NEURONS; OLIGOSACCHARIDES; OXIDATIVE STRESS; PEPTIDE FRAGMENTS; RATS; RATS, SPRAGUE-DAWLEY; SUPEROXIDE DISMUTASE;

EID: 84953635985     PISSN: 01418130     EISSN: 18790003     Source Type: Journal    
DOI: 10.1016/j.ijbiomac.2015.11.011     Document Type: Article

References (51)

1. 1-42) induce the activation of cyclooxygenase-2 in astrocytes via an interaction with interleukin-1β, tumour necrosis factor-α, and a nuclear factor κ-B mechanism in the rat brain. Exp. Neurol. 2012, 236:215-227.
2. Prince M., Bryce R., Albanese E., Wimo A., Ribeiro W., Ferri C.P. The global prevalence of dementia: a systematic review and meta analysis. Alzheimers Dement. 2013, 9:63-75.e2.
3. Prince M., Wimo A. World Alzheimer Report 2015: the global impact of dementia 2015, 1-82. Alzheimer's Disease International.
4. Mecocci P., Polidori M.C. Antioxidant clinical trials in mild cognitive impairment and Alzheimer's disease. Biochim. Biophys. Acta 2012, 1822:631-638.
5. Wang C.M., Liu M.Y., Wang F., Wei M.J., Wang S., Wu C.F., Yang J.Y. Anti-amnesic effect of pseudoginsenoside-F11 in two mouse models of Alzheimer's disease. Pharmacol. Biochem. Behav. 2013, 106:57-67.
6. Huang Y., Mucke L. Alzheimer mechanisms and therapeutic strategies. Cell 2012, 148:1204-1222.
7. 1-42 oligomers injected into the hippocampus. Horm. Behav. 2013, 64:477-486.
8. Morris M., Maeda S., Vossel K., Mucke L. The many faces of tau. Neuron 2011, 70:410-426.
9. Winner B., Jappelli R., Maji S.K., Desplats P.A., Boyer L., et al. In vivo demonstration that alpha-synuclein oligomers are toxic. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:4194-4199.
10. Ji C., Aisa H.A., Yang N., et al. Gossypium herbaceam extracts inhibited NF-kappaB activation to attenuate spatial memory impairment and hippocampal neurodegeneration induced by amyloid-beta in rats. J. Alzheimers Dis. 2008, 14:271-283.
11. Cleary J.P., Walsh D.M., Hofmeister J.J., Shankar G.M., Kuskowski M.A., Selkoe D.J., Ashe K.H. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat. Neurosci. 2005, 8:79-84.
12. Klyubin I., Walsh D.M., Cullen W.K., Fadeeva J.V., Anwyl R., Selkoe D.J., Rowan M.J. Soluble Arctic amyloid beta protein inhibits hippocampal long-term potentiation in vivo. Eur. J. Neurosci. 2004, 19:2839-2846.
13. O'Hare E., Scopes D.I., Treherne J.M. Novel anti-inflammatory compound SEN1176 alleviates behavioral deficits induced following bilateral intrahippocampal injection of aggregated amyloid-β1-42. J. Alzheimers Dis. 2011, 25:219-229.
14. De La Monte S.M., Wands J.R. Molecular indices of oxidative stress and mitochondrial dysfunction occur early and often progress with severity of Alzheimer's disease. J. Alzheimers Dis. 2006, 9:167-181.
15. Butterfield D.A., Drake J., Pocernich C., Castegna A. Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide. Trends Mol. Med. 2001, 7:548-554.
16. Perry V.H., Nicoll J.A., Holmes C. Microglia in neurodegenerative disease. Nat. Rev. Neurol. 2010, 6:193-201.
17. Sies H. Oxidative stress: introductory remarks. Oxidative Stress 1985, 1-8. Academic Press, London.
18. Mariani E., Polidori M.C., Cherubini A., Mecocci P. Oxidative stress in brain aging, neurodegenerative and vascular diseases: an overview. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 2005, 827:65-75.
19. Mangialasche F., Polidori M.C., Monastero R., Ercolani S., Camarda C., Cecchetti R., Mecocci P. Biomarkers of oxidative and nitrosative damage in Alzheimer's disease and mild cognitive impairment. Ageing Res. Rev. 2009, 8:285-305.
20. Kern A., Behl C. The unsolved relationship of brain aging and late-onset Alzheimer disease. Biochim. Biophys. Acta 2009, 1790:1124-1132.
21. Wilkinson B.L., Cramer P.E., Varvel N.H., Reed-Geaghan E., Jiang Q., et al. Ibuprofen attenuates oxidative damage through NOX2 inhibition in Alzheimer's disease. Neurobiol. Aging. 2012, 33(197):e21-e32.
22. Monje M.L., Mizumatsu S., Fike J.R., Palmer T.D. Irradiation induces neural precursor- cell dysfunction. Nat. Med. 2002, 8:955-962.
23. Monje M.L., Toda H., Palmer T.D. Inflammatory blockade restores adult hippocampal neurogenesis. Science 2003, 302:1760-1765.
24. Longpre F., Garneau P., Christen Y., Ramassamy C. Protection by EGb 761 against beta-amyloid-induced neurotoxicity: involvement of NF-kappaB, SIRT1, and MAPKs pathways and inhibition of amyloid fibril formation. Free Radic. Biol. Med. 2006, 41:1781-1794.
25. Pae H.O., Seo W.G., Kim N.Y., Oh G.S., et al. Induction of granulocytic differentiation in acute promyelocytic leukemia cells (HL-60) by water-soluble chitosan oligomer. Leuk Res. 2001, 25:339-346.
26. Yoon N.Y., Ngo D.N., Kim S.K. Acetylcholinesterase inhibitory activity of novel chitooligosaccharide derivatives. Carbohydr. Polym. 2009, 78:869-872.
27. Joodi G., Ansari N., Khodagholi F. Chitooligosaccharide-mediated neuroprotection is associated with modulation of Hsps expression and reduction of MAPK phosphorylation. Int. J. Biol. Macromol. 2011, 48:726-735.
28. Pangestuti R., Kim S.K. Neuroprotective properties of chitosan and its derivatives. Mar. Drugs 2010, 8:2117-2128.
29. Liu H.T., Li W.M., Li X.Y., et al. Chitosanoligosaccharides inhibit the expression of interleukin-6 in lipopolysaccharide-induced human umbilical vein endothelial cells through p38 and ERK1/2 protein kinases. Basic Clin. Pharm. Toxicol. 2010, 106:362-371.
30. Yuan W.P., Liu B., Liu C.H., Wang X.J., Zhang M.S., Meng X.M., Xia X.K. Antioxidant activity of chito-oligosaccharides on pancreatic islet cells in streptozotocin-induced diabetes in rats. World J. Gastroenterol. 2009, 15:1339-1345.
31. Chen Q., Liu S.Q., Du Y.M., Peng H., Sun L.P. Carboxymethyl-chitosanprotects rabbit chondrocytes from interleukin-1beta-induced apoptosis. Eur. J. Pharmacol. 2006, 541:1-8.
32. Zhang J., Xia W., Liu P., Cheng Q., Tahi T., Gu W., Li B. Chitosan modification and pharmaceutical/biomedical applications. Mar. Drugs 2010, 8:1962-1987.
33. Xu W., Huang H.C., Lin C.J., Jiang Z.F. Chitooligosaccharides protect rat cortical neurons against copper induced damage by attenuating intracellular level of reactive oxygen species. Bioorg. Med. Chem. Lett. 2010, 20:3084-3088.
34. Dai X., Chang P., Zhu Q., et al. Chitosan oligosaccharides protect rat primary hippocampal neurons from oligomeric β-amyloid 1-42-induced neurotoxicity. Neurosci. Lett. 2013, 554:64-69.
35. Stine W.B., Dahlgren K.N., Krafft G.A., LaDu M.J. In vitro characterization of conditions for amyloid-peptide oligomerization and fibrillogenesis. J. Biol. Chem. 2003, 278:11612-11622.
36. Yu Y., Zhou L., Sun M., Zhou T., Zhong K., Wang H., et al. Xylocoside G reduces amyloid-induced neurotoxicity by inhibiting NF-kappaB signaling pathway in neuronal cells. J. Alzheimers Dis. 2012, 30:263-275.
37. Paxinos G., Watson C. The rat brain in stereotaxic coordinates. Vet. Pathol. 1998, 43:86-87.
38. Morris R. Developments of a water-maze procedure for studying spatial learning in the rat. J. Neurosci. Methods 1984, 11:47-60.
39. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
40. Wei L., Lv S., Huang Q., et al. Pratensein attenuates Aβ-induced cognitive deficits in rats: enhancement of synaptic plasticity and cholinergic function. Fitoterapia 2015, 101:208-217.
41. Blennow K., de Leon M.J., Zetterberg H. Alzheimer's disease. Lancet 2006, 368:387-403.
42. Glabe C.G. Conformation-dependent antibodies target diseases of protein misfolding. Trends Biochem. Sci. 2004, 29:542-547.
43. O'Nuallain B., Wetzel R. Conformational Abs recognizing a generic amyloid fibril epitope. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:1485-1490.
44. Soto C. Unfolding the role of protein misfolding in neurodegenerative diseases. Nat. Rev. Neurosci. 2003, 4:49-60.
45. Kim T.I., Lee Y.K., Park S.G., Choi I.S., Ban J.O., Park H.K., et al. l-Theanine, an amino acid in green tea, attenuates β-amyloid-induced cognitive dysfunction and neurotoxicity: reduction in oxidative damage and inactivation of ERK/p38 kinase and NF-κB pathways. Free Radic. Biol. Med. 2009, 47:1601-1610.
46. Gu F., Zhu M., Shi J., Hu Y., Zhao Z. Enhanced oxidative stress is an early event during development of Alzheimer-like pathologies in presenilin conditional knock-out mice. Neurosci. Lett. 2008, 440:44-48.
47. Markesbery W.R. Oxidative stress hypothesis in Alzheimer's disease. Free Radic. Biol. Med. 1997, 23:134-147.
48. bdul A.H., Sultana R., Keller J.N., St Clair D.K., et al. Mutations in amyloid precursor protein and presenilin-1 genes increase the basal oxidative stress in murine neuronal cells and lead to increased sensitivity to oxidative stress mediated by amyloid beta-peptide(1-42), HO and kainic acid: implications for Alzheimer's disease. J. Neurochem. 2006, 96:1322-1335.
49. Chauhan V., Chauhan A. Oxidative stress in Alzheimer's disease. Pathophysiology 2006, 13:195-208.
50. Cardoso S.M., Oliveira C.R. Glutathione cycle impairment mediates A beta-induced cell toxicity. Free Radic. Res. 2003, 37:241-325.
51. Farfara D., Lifshitz V., Frenkel D. Neuroprotective and neurotoxic properties of glial cells in the pathogenesis of Alzheimer's disease. J. Cell Mol. Med. 2008, 12:762-780.